CDMO Blog

close

Subscribe to Email Updates

Popular Stories

Viral Aggregation in Downstream Processing of Lentiviral Vectors
IQ, OQ and PQ: Why Are They Important in the Manufacturing of Cell and Gene Therapies?
CDMOs: The Good, the Great and the Exceptional (and How to Tell the Difference)
Five Steps to Ensure Your Cell and Gene Therapy Product Is GMP Compliant
5 Considerations for Scaling-Up PSC-Derived Cell Therapies
30 Oct 2019

Concentration and Reformulation of Cellular Immunotherapies – A Major Downstream Processing Step

Cellular immunotherapies (e.g. CAR-T cells) are primarily used as an a...

24 Oct 2019

How Can a Closed CAR-T Manufacturing Process De-Risk Your Process, Reduce Costs and Improve Efficiency?

In a previous post we introduced chimeric antigen receptor T-cell (CAR...

Tell us what you thought about this post.